THE WOODLANDS, Texas--(BUSINESS WIRE)--
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company
developing personalized immunotherapies for autoimmune disorders,
including multiple sclerosis (MS) and neuromyelitis optica (NMO), today
announced that Neil K. Warma, Opexa’s President and Chief Executive
Officer, has been invited as a panel member to participate in the New
York CEO Conference. The event will take place November 12 - 13, 2014,
at the Apella in New York.
Mr. Warma will join other experts in the field of personalized medicine
as they discuss the numerous advances that are being made in the
industry and the implications for drug development, in the panel
discussion, "How is Personalized Medicine Guiding Drug
Development in 2014?"
The New York CEO Biotech Conference is a forum for industry Chief
Executive Officers and decision makers in the life sciences. This
invitation-only conference features luminaries in medicine and research,
as well as executives of the next generation of leading biotechnology
and pharmaceutical companies, who will explore the most relevant issues
facing the industry today. Panel topics include outlooks on the 2015
healthcare industry, accelerating translation of research discoveries,
financing trends and strategies, innovation in drug discovery,
personalized medicine, innovative deal structures and more.
About Opexa
Opexa is a biopharmaceutical company developing personalized
immunotherapies with the potential to treat major illnesses, including
multiple sclerosis (MS) as well as other autoimmune diseases, such as
neuromyelitis optica (NMO). These therapies are based on Opexa’s
proprietary T-cell technology. The Company’s leading therapy candidate,
Tcelna®, is a personalized T-cell immunotherapy that is in a
Phase IIb clinical development program (the Abili-T trial) for the
treatment of Secondary Progressive MS. Tcelna is derived from T-cells
isolated from the patient’s peripheral blood, expanded ex vivo,
and reintroduced into the patients via subcutaneous injections. This
process triggers a potent immune response against specific subsets of
autoreactive T-cells known to attack myelin. Opexa’s mission is to lead
the field of Precision Immunotherapy® by aligning the
interests of patients, employees and shareholders.
For more information visit the Opexa Therapeutics website at www.opexatherapeutics.com.
Source: Opexa Therapeutics, Inc.